Pranjali Dalvi1, Amy O'Brien-Ladner, Navneet K Dhillon. 1. Division of Pulmonary and Critical Care Medicine, Department of Medicine (P.D., A.O'B.-L., N.K.D.) and Department of Molecular and Integrative Physiology (N.K.D.), University of Kansas Medical Center, Kansas City, KS.
Abstract
OBJECTIVE: Our previous findings support an additive effect of cocaine to HIV infection in the development of pulmonary arteriopathy through enhanced proliferation of human pulmonary smooth muscle cells. We now examined the role of antiproliferative bone morphogenetic protein receptor (BMPR) axis in HIV protein and cocaine-mediated pulmonary smooth muscle hyperplasia. APPROACH AND RESULTS: Stimulation of BMPR axis resulted in attenuation of synergistic increase in the proliferation of human pulmonary arterial smooth muscle cells in response to cocaine and HIV protein, transactivator of transcription (Tat). Interestingly, an increase in mRNA but decrease in protein levels of BMPR with correlated decrease in the activation of Sma- and MAD-related family protein 1/5/8 and Id1 gene expression was observed on combined treatment with cocaine and Tat when compared with the untreated cells at all time points tested. Although longer exposure to either cocaine or Tat alone also resulted in a significant decrease in the BMPR protein expression, the abrogation on combined treatment was still significantly more when compared with that of the monotreatments. Significant increase in mRNA but downmodulation of BMPR protein expression was also observed in the lung extracts from HIV-infected intravenous drug users (HIV+IVDU) when compared with that from HIV-infected non-IVDUs (HIV) or uninfected IVDUs (IVDU). Furthermore, significant decrease in BMPR protein expression was also observed in HIV or IVDUs when compared with normal controls that correlated with in vitro findings on chronic exposure to cocaine or HIV protein alone. CONCLUSIONS: Simultaneous exposure of pulmonary smooth muscle cells to viral protein(s) and cocaine exacerbates downregulation of BMPR axis that may result in enhanced pulmonary vasculature aberrations in HIV+IVDUs.
OBJECTIVE: Our previous findings support an additive effect of cocaine to HIV infection in the development of pulmonary arteriopathy through enhanced proliferation of human pulmonary smooth muscle cells. We now examined the role of antiproliferative bone morphogenetic protein receptor (BMPR) axis in HIV protein and cocaine-mediated pulmonary smooth muscle hyperplasia. APPROACH AND RESULTS: Stimulation of BMPR axis resulted in attenuation of synergistic increase in the proliferation of human pulmonary arterial smooth muscle cells in response to cocaine and HIV protein, transactivator of transcription (Tat). Interestingly, an increase in mRNA but decrease in protein levels of BMPR with correlated decrease in the activation of Sma- and MAD-related family protein 1/5/8 and Id1 gene expression was observed on combined treatment with cocaine and Tat when compared with the untreated cells at all time points tested. Although longer exposure to either cocaine or Tat alone also resulted in a significant decrease in the BMPR protein expression, the abrogation on combined treatment was still significantly more when compared with that of the monotreatments. Significant increase in mRNA but downmodulation of BMPR protein expression was also observed in the lung extracts from HIV-infected intravenous drug users (HIV+IVDU) when compared with that from HIV-infected non-IVDUs (HIV) or uninfected IVDUs (IVDU). Furthermore, significant decrease in BMPR protein expression was also observed in HIV or IVDUs when compared with normal controls that correlated with in vitro findings on chronic exposure to cocaine or HIV protein alone. CONCLUSIONS: Simultaneous exposure of pulmonary smooth muscle cells to viral protein(s) and cocaine exacerbates downregulation of BMPR axis that may result in enhanced pulmonary vasculature aberrations in HIV+IVDUs.
Authors: Hilario Nunes; Marc Humbert; Olivier Sitbon; Jane H Morse; Zemin Deng; James A Knowles; Catherine Le Gall; Florence Parent; Gilles Garcia; Philippe Hervé; Robyn J Barst; Gérald Simonneau Journal: Am J Respir Crit Care Med Date: 2003-02-25 Impact factor: 21.405
Authors: B Ensoli; L Buonaguro; G Barillari; V Fiorelli; R Gendelman; R A Morgan; P Wingfield; R C Gallo Journal: J Virol Date: 1993-01 Impact factor: 5.103
Authors: Victoria N Parikh; Joseph Park; Ivana Nikolic; Richard Channick; Paul B Yu; Teresa De Marco; Priscilla Y Hsue; Stephen Y Chan Journal: J Acquir Immune Defic Syndr Date: 2015-11-01 Impact factor: 3.731
Authors: Lars C Huber; Silvia Ulrich; Caroline Leuenberger; Max Gassmann; Johannes Vogel; Leonardo Glutz von Blotzheim; Rudolf Speich; Malcolm Kohler; Matthias Brock Journal: Exp Biol Med (Maywood) Date: 2015-04-07
Authors: Sharilyn Almodovar; Jessica Swanson; Luis D Giavedoni; Sreetharan Kanthaswamy; Carlin S Long; Norbert F Voelkel; Michael G Edwards; Joy M Folkvord; Elizabeth Connick; Susan V Westmoreland; Paul A Luciw; Sonia C Flores Journal: Viral Immunol Date: 2017-12-19 Impact factor: 2.257
Authors: Emilia M Swietlik; Matina Prapa; Jennifer M Martin; Divya Pandya; Kathryn Auckland; Nicholas W Morrell; Stefan Gräf Journal: Genes (Basel) Date: 2020-11-26 Impact factor: 4.096